U.S. Markets closed
  • S&P Futures

    3,855.25
    +10.25 (+0.27%)
     
  • Dow Futures

    31,142.00
    +46.00 (+0.15%)
     
  • Nasdaq Futures

    13,370.00
    +75.75 (+0.57%)
     
  • Russell 2000 Futures

    2,157.90
    +0.20 (+0.01%)
     
  • Crude Oil

    53.28
    +0.04 (+0.08%)
     
  • Gold

    1,872.00
    +5.50 (+0.29%)
     
  • Silver

    25.99
    +0.22 (+0.85%)
     
  • EUR/USD

    1.2133
    +0.0018 (+0.1456%)
     
  • 10-Yr Bond

    1.0900
    -0.0020 (-0.18%)
     
  • Vix

    21.58
    -1.66 (-7.14%)
     
  • GBP/USD

    1.3683
    +0.0028 (+0.2053%)
     
  • USD/JPY

    103.5240
    -0.0460 (-0.0444%)
     
  • BTC-USD

    34,691.98
    +29.37 (+0.08%)
     
  • CMC Crypto 200

    688.76
    -11.85 (-1.69%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,727.48
    +204.22 (+0.72%)
     

ICPT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 4, 2021 in the Class Action Filed on Behalf of Intercept Pharmaceuticals, Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - December 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) alleging that the Company violated federal securities laws.

Class Period: September 28, 2019 and October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

Learn more about your recoverable losses in ICPT:
http://www.kleinstocklaw.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?id=11724&from=5

The filed complaint alleges that Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Shareholders have until January 4, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the ICPT lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70753